Brief: SCHOTT Pharma Sees FY EBITDA Margin Around 28%
05/08/2025 08:55
Aug 5 (Reuters) - SCHOTT Pharma AG & Co KgaA 1SXP.DE: EQS-ADHOC: SCHOTT PHARMA AG & CO. KGAA: SCHOTT PHARMA SPECIFIES FY 2025 GUIDANCE FOR REVENUE GROWTH AND EBITDA MARGIN SCHOTT PHARMA AG & CO KGAA - EXPECTS FY 2025 EBITDA MARGIN AROUND 28.0% SCHOTT PHARMA AG & CO KGAA - ORGANIC REVENUE GROWTH FOR FY 2025 IS EXPECTED TO BE AROUND 6.0%, AT LOWER END OF MANAGEMENT EXPECTATIONS BETWEEN 6.0% AND 9.0% Source text: ID:nEQ6PDxJ7a Further company coverage: 1SXP.DE (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))